Contact Information
Address (Office) E12-4006  
(Lab) N22-3001
Phone (Office) 8822 4991
(Lab) 8822 4219
Fax 8822 2314
Email hfkwok@um.edu.mo
Website http://www.henrykwoklab.com/
Education
PhD in Biomedical Sciences University of Ulster, UK (2003)
BSc (1st Class Hons) in Biotechnology University of Ulster, UK (2000)
NVQ Level 4 (Higher National Diploma) in Management Chartered Management Institute, UK (2007)
Positions
2018-Present Associate Professor, Faculty of Health Sciences, University of Macau
2014-present Choi Kai Yau College (CKYC) Fellow, University of Macau
2013-present Visiting Scientist, Cancer Research UK Cambridge Institute, University of Cambridge, UK
2014-2018 Assistant Professor, Faculty of Health Sciences, University of Macau
2007-2017 Visiting Research Fellow, School of Pharmacy, Queen’s University Belfast, UK
2011-2014 Senior Research Associate / Fellow, Department of Oncology / Cancer Research UK Cambridge Institute, University of Cambridge, UK
2007-2011 Senior Scientist, Fusion Antibodies Ltd., UK
2004-2007 Knowledge Transfer & Research Scientist, School of Pharmacy, Queen’s University Belfast, UK
Research Interests
Prof Kwok’s research interests mainly focus on the development of novel monoclonal antibodies and venom-based peptides as prototype drugs for anti-cancer and anti-inflammatory therapies. In addition, Prof. Kwok’s research group is also expanding scientific knowledge and research in the areas of existing and novel cancer biomarkers such as 1) matricellular protein — OPN, 2) metalloproteinase — ADAM17 & ADAMTS5, 3) DNA replication licensing factor — MCM proteins, 4) small GTP binding protein — RAN, as well as immunotherapy markers (e.g. PD-1/PD-L1) in order to identify and validate their prognostic and therapeutic values according to the roles in hallmarks of cancer. For more details, please kindly visit Faculty of Health Sciences (FHS) Newsletter link — Principle Investigator (PI) Introduction Series as below:
https://mp.weixin.qq.com/s/jNol5GBHnYXzl6h2s6LL7Q
Selected Publications
Journal Articles:
  • Jameel Mughal M., Mahadevappa R and Kwok H. F.* (2018) DNA replication licensing proteins: saints and sinners in cancer. Seminars in Cancer Biology (In Press) https://doi.org/10.1016/j.semcancer.2018.11.009
  • Rajendran B. K., Suresh M. X., Bhaskaran S. P., Harshitha Y., Gaur U. and Kwok H. F.* (2018) Pharmacoinformatic approach to explore the antidote potential of phytochemicals on bungarotoxin from Indian krait, Bangarus caeruleus. Computational and Structural Biotechnology Journal 16: 450-461.
  • Lyu P., Ge L., Ma R., Wei R., McCrudden C. M., Chen T., Shaw C. and Kwok H. F.* (2018) Identification and pharmaceutical evaluation of novel frog skin-derived serine proteinase inhibitor peptide — PE-BBI (Pelophylax esculentus Bowman-Birk inhibitor) for the potential treatment of cancer. Scientific Reports 8(1):14502.
  • Mahadevappa R., Neves H., Yuen S. M., Jameel M., Bai Y., Yuen H. F., Zhang S. D., Zhu Y., Lin Y. and Kwok H. F.* (2018) DNA replication licensing protein MCM10 promotes tumor progression and is a novel prognostic biomarker and potential therapeutic target in breast cancer. Cancers 10(9): 282.
  • Li B., Lyu P., Xi X., Ge L., Mahadevappa R., Shaw C. and Kwok H. F.* (2018) Triggering of cancer cell cycle arrest by a novel scorpion venom-derived peptide — Gonearrestide. Journal of Cellular and Molecular Medicine 22(9) 4460-4473.
  • Wei R., Wong J. P. C., Lyu P., Xi X., Tong O. L. H., Zhang S. D., Yuen H. F., Shirasawa S. and Kwok H. F.* (2018) In vitro and clinical data analysis of Osteopontin as a prognostic indicator in colorectal cancer. Journal of Cellular and Molecular Medicine 22(9): 4097-4105.
  • Huang Y., Zhang Y., Ge L., Lin Y.*and Kwok H. F.* (2018). The Role of Protein Tyrosine Phosphatases in Hepatocellular Carcinoma. Cancers 10(3): 82.
  • Wang Q., Lin W., Tang X., Li S., Guo L., Lin Y.* and Kwok H. F.* (2017) The roles of microRNAs in regulating the expression of PD-1/PD-L1 immune checkpoint. International Journal of Molecular Sciences 18(12): 2540.
  • Zhong H., Chen B., Neves H., Xing J., Ye Y., Lin Y., Zhuang G., Zhang S. D., Huang J. and Kwok H. F.* (2017) Expression of minichromosome maintenance genes in renal cell carcinoma. Cancer Management and Research 9: 637-647.
  • Wong J. P. C., Wei R., Lyu P., Tong O. L. H., Zhang S. D., Wen Q., Yuen H. F., El-Tanani M. and Kwok H. F.* (2017) Clinical and in vitro analysis of Osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer. International Journal of Biological Sciences 13(11): 1373-1386.
  • Ling Y., Chen J., Guo L., Wang C., Tan W., Wen Q., Zhang S. D., Deng G.*, Lin Y.* and Kwok H. F.* (2017) β-defensin 1 expression in HCV infected liver/liver cancer: an important role in protecting HCV progression and liver cancer development. Scientific Reports 7(1): 13404.
  • Mahadevappa R., Ma R. and Kwok H. F.* (2017) Venom peptides — Improving specificity for cancer therapy. Trends in Cancer 3(9): 611-614.
  • Wei R., Wong J.P.C. and Kwok H. F.* (2017) Osteopontin — a promising biomarker for cancer therapy. Journal of Cancer 8(12): 3173-2183.
  • Neves H. and Kwok H. F.* (2017) In sickness and in health: The many roles of the minichromosome maintenance proteins. BBA – Reviews on Cancer 1868(1): 295-308.
  • Ye J., Yuen S. M., Murphy G., Xie R.* andKwok H. F.* (2017) Anti-Tumour Effects of a ‘Human & Mouse Cross-Reactive’ Anti-ADAM17 Antibody in a Pancreatic Cancer Model In Vivo. European Journal of Pharmaceutical Sciences pii: S0928-0987(17)30297-X. doi: 10.1016/j.ejps.2017.05.057.
  • Takayanagi T., Forrester S. J., Kawai T., Obama T., Tsuji T., Elliott K. J., Nuti E., Rossello A., Kwok H. F., Scalia R., Rizzo V. and Eguchi S. (2016)Vascular ADAM17 as a Novel Therapeutic Target in Mediating Cardiovascular Hypertrophy and Perivascular
  • Yuen S. M. and Kwok H. F.* (2016) Temporal establishment of neural cell identity in vivo and in vitro. Journal of Tissue Engineering and Regenerative Medicine. doi: 10.1002/term.2158.
  • Zhang S. D., Leung K. L., McCrudden C. M. and Kwok H. F.* (2015) The prognostic significance of combining VEGFA, FLT1 and KDR mRNA expressions in brain tumors. Journal of Cancer. 6(9): 812-818.
  • Huang Y., Zhang S. D., McCrudden C. M., Chan K. W., Lin Y. and Kwok H. F.* (2015) The prognostic significance of PD-L1 in bladder cancer. Oncology Reports. 33: 3075-3084.
  • Neves H. and Kwok H. F.* (2015) Recent advances in the field of anti-cancer immunotherapy. BBA Clinical. 3: 280-288.
  • Xi X., Li B., Chen T. and Kwok H. F.* (2015) A Review on Bradykinin-Related Peptides Isolated from Amphibian Skin Secretion. Toxins. 7(3): 951-970.
  • Kwok H .F.*, Zhang S. D., McCrudden C. M., Yuen H. F., Ting K. P., Wen Q., Khoo U.S.* and Chan K. Y. K.* (2015) Prognostic significance of minichromosome maintenance proteins in breast cancer. American Journal of Cancer Research. 5(1): 52-71.
  • Huang Y., Benaich B., Tape C .J., Kwok H. F.* and Murphy G.* (2014) Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation. International Journal of Biological Sciences. 10(7): 702-714.
  • Kwok H. F.*, Botkjaer K. A., Tape C. J., Huang Y., McCafferty J. and Murphy G. (2014) Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy. PEDS 27(6): 179-190.
  • van’t Wout E. F. A., Dickens J. A., van Schadewijk A., Haq I., Kwok H. F., Ordóñez A., Murphy G., Stolk J., Lomas D. A., Hiemstra P. S. and Marciniak S. J. (2014) Excess ERK signalling promotes inflammatory signalling in primary airway epithelium expressing Z α1-antitrypsin. Human Molecular Genetics 23(4): 292-241.
  • Kwok H. F.*, Buick R. J.*, Kuehn D., Gormely J. A., Doherty D., Jaquin T. J., McClurg A., Ward C., Byrne T., Jaworski J., Leung K. L., Snoddy P., McAnally C., Burden R. E., Gray B., Lowry J., Sermadiras I., Gruszka N., Courtenay-Luck N., Kissenfennig A., Scott C. J., Johnston J. A. and Olwill S. A. (2011) Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity. Molecular Cancer 10(1):147.
  • Fry B. G., Winter K., Norman J. A., Roelants K., Nabuurs R. J. A., van Osch M. J. P., Teeuwisse W. M., van der Weerd L., McNaughtan J. E., Kwok H. F., Scheib H., Greisman L., Kochva E., Miller L. J., Gao F., Karas J., Scanlon D., Lin F., Kuruppu S., Shaw C., Wong L., Kuruppu S. and Hodgson W. C. (2010) Functional and structural diversification of Anguimorpha lizard venom system. Molecular & Cellular Proteomics 9(11):2369-2390.
  • Fry B.G., Roelants K., Winter K., Hodgson W. C., Griesman L., Kwok H. F., Scanlon D., Karas J., Shaw C., Wong L., Norman J. A. (2010) Novel venom proteins produced by differential domain-expression strategies in Beaded lizards and Gila monsters (genus Heloderma). Molecular Biology and Evolution 27(2): 395-407.
  • Fry B. G., Teeuwisse W, Van Osch M. J. P., Scheib H, Winter K. L., Greisman L., Roelants K, Van der Weerd L., Clemente C. J., Giannakis E., Hodgson W. C., Luz S., Martelli P., Krishnasamy K., Kochva E., Kwok H. F., Scanlon D., Karas J., Citron D. M., Goldstein E. J. C., Mcnaughtan J. E. and Norman J. (2009) Central role for venom in predation by the Komodo Dragon and the giant extinct Megalania. PNAS 106(22): 8969-8974.
  • Kwok H. F.*, Chen T., O’Rourke M., Ivanyi C., Hirst D. and Shaw C. (2008) Helokinestatin: a novel bradykinin B2 receptor antagonist decapeptide from lizard venom. Peptides 29: 65-72.
  • Chen T., Bjourson A. J., Orr D. F., Kwok H. F., Ping F., Ivanyi C. and Shaw C. (2002) Unmasking venom gland transcriptomes in reptile venoms. Analytical Biochemistry 311: 152-156.
Book Chapters:

  • Fry B. G., Roelants K., Jackson T. N. W., Takacs Z., Reeks T. and Kwok H. F.* (2015) Chapter 18 B-Type natriuretic peptides. In Bryan Fry (Ed.), Venomous Reptiles and Their Toxins (pp. 312-317). Oxford, UK: Oxford University Press.
  • Fry B. G., Roelants K., Jackson T. N. W., Takacs Z., Reeks T. and Kwok H. F.* (2015) Chapter 11 Exendin peptides. In Bryan Fry (Ed.), Venomous Reptiles and Their Toxins (pp. 247-254). Oxford, UK: Oxford University Press.

*corresponding author

Full publications list
Research Grants 
2017-2020 The Science and Technology Development Fund (FDCT), Discover & investigate the role of novel venom-based peptide(s) in cancer progression to unlock its mechanism as a therapeutic drug development to fight against cancer.
2017-2020 The Science and Technology Development Fund (FDCT) — Minister of Science and Technology of China (MOST), Investigation of the correlation between PD-L1 expression and KRAS signaling pathway and its potential clinical application.
2015-2018 The Science and Technology Development Fund (FDCT), Investigate the role of MCM10 in breast cancer progression & its potential as a therapeutic target.
2015-2018 University of Macau Multi-Year Research Grant, A model system for structural and functional convergence of venom peptides: unlock a new era in drug development.
2015–2018 University of Macau Multi-Year Research Grant, Osteopontin (OPN) expression as a prognostic indicator in colorectal cancer & its potential as a therapeutic target
2014-2016 University of Macau Start-Up Research Grant, Investigate novel regulator(s) for ADAM17 ectodomain shedding by cellular & proteomics approaches: Evaluation in biology and medicine.
2011-2016 Cancer Research UK Research Grant (with Prof Gillian Murphy), Development of human TACE (mouse & human cross-reactive) therapeutic antibody against cancer.
2007-2011 Invest Northern Ireland (NI) European Development Research Fund, Discovery, development & evaluation of the therapeutic efficacy of APO-1 antibody and human Cathepsin S antibody for the treatment of cancer.
2006-2009 InterTrade Ireland Innova Grant, TB diagnostic kit/assay development
2004-2007 UK Technology Strategy Board KTP Funding, Define the shortfalls in current protein production techniques, and to develop novel techniques to permit more efficient and scaled protein engineering, protein expression and protein purification
Patents
  1. Olwill S. A., Kwok H. F., Johnston J. A., Whelan C., Clarke J., Shuralev E. (2010) Diagnostic methods and kits – The identification of tuberculosis infection in animals such as badgers, cervids and wild boar. Patent WO 2010097625
  2. Olwill S. A., Buick R., Kwok H. F., Scott C., Ward C. (2010) Antibody Therapy – Described are methods of inhibiting angiogenesis, the methods comprising the simultaneous, sequential or separate administration of (i) an anti- Cathepsin S antibody molecule, and (ii) an anti-VEGF antibody molecule. Also described are anti-Cathepsin S humanized antibodies, pharmaceutical compositions and methods of treatment using such antibodies. Patent WO 2010094981
  3. Olwill S. A., Johnston J. A., Kwok H. F., Whelan C, Clarke J. (2009) Diagnostic method and kit – The invention relates to methods for diagnosis of tuberculosis comprising determining the presence or absence of, or an immune response to a group of antigens. Patent WO2009024822
  4. Olwill S. A., Buick R. J., Kwok H. F., Johnston J. A. (2006) Assays for diagnosis of tuberculosis and uses thereof – The identification of mycobacterial antigens which are highly immunogenic and which may be used in assays and methods for the diagnosis of tuberculosis. Patent WO2006117538
Awards
2018 University of Macau Incentive Scheme Award
2017-2018 Faculty of Health Sciences Best Teacher (Excellence in Service) Award
2014 Winner of Protein Discovery Summit Poster Presentation:
GTC’s 2nd Antibody & Protein Therapeutics Conference
2011-2014 CRUK Research Fellowship
2008 Winner of Knowledge Transfer Partnership (KTP) Regional Award
2004-2007 Knowledge Transfer Partnerships (KTP) Fellowship
2000-2003 Vice-Chancellor Research Scholarship
1999 University of Ulster Overseas student Bursary Award
Professional Activities
Society Membership:

  • Antibody Society
  • Biochemical Society
  • International Society on Toxinology
  • Institute of Biomedical Science
  • Chartered Management Institute
  • American Association for Cancer Research
Ad Hoc Reviewer of Journals:

  • Seminars in Cancer
  • Advances in Modern Oncology Research
  • BMC Urology
  • BMC Molecular Biology
  • Breast Cancer Targets and Therapy
  • Biomedicine & Pharmacotherapy
  • Biomarkers in Medicine
  • British Journal of Medicine and Medical Research
  • Cell Death and Disease
  • Cancers
  • Cancer Biomarkers
  • Cancer Biology & Medicine
  • Cancer Management & Research
  • Cancer Informatics
  • Cellular and Molecular Life Sciences
  • Cell Biology International
  • Cellular Physiology and Biochemistry
  • Computational & Structural Biotechnology Journal
  • Current Pharmaceutical Biotechnology
  • Current Drug Targets
  • Current Protein & Peptide Science
  • Current Enzyme Inhibition
  • Cancer Biology & Treatment
  • Experimental and Therapeutic Medicine
  • Future Oncology
  • IUBMB Life
  • International Journal of Biological Sciences
  • International Journal of Biochemistry Research & Review
  • International Journal of Nanomedicine
  • International Journal of Oncology
  • Journal of Cell Science & Therapy
  • Journal of Cellular and Molecular Medicine
  • Journal of Cancer
  • Journal of Molecular Evolution
  • Journal of Ovarian Research
  • Journal of Thoracic Disease
  • Journal of Venom Research
  • Langenbeck’s Archives of Surgery
  • mAbs
  • Microbial Pathogenesis
  • Molecular Biotechnology
  • Molecular Biology Reports
  • Molecular Medicine Reports
  • Molecules
  • Mutation Research
  • OncoTargets & Therapy
  • Oncology Reports
  • Oncology Letters
  • Oncotarget
  • PeerJ
  • PLoS One
  • PNAS
  • Peptides
  • Pharmacology & Therapeutics
  • Regulatory Peptide
  • Research in Veterinary Science
  • Scientific Reports
  • Tumor Biology
  • Toxins
  • Toxicon
  • Theranostics
Reviewer of Book Chapter:

  • Bioactive Natural Products — Elsevier Science Publishers, Amsterdam
Invited External Examiners:

  • School of Pharmacy, Queen’s University Belfast, UK — PhD programme
  • Li Ka Shing Faculty of Medicine, University of Hong Kong — MMedSc programme
  • Faculty of Medicine, Nursing & Health Sciences, Monash University, Australia — PhD programme
Invited Editorial Service:

  • Editorial Board Member of Toxins (ISSN 2072-6651)
  • Editorial Board Member of Recent Patents on Anti-Cancer Drug Discovery (ISSN 2212-3970)
  • Editorial Board Member of Current Protein & Peptide Science (ISSN 1389-2037)
  • Editorial Board Member of Biomolecules (ISSN 2218-273X)
  • Editorial Board Member of Advances in Modern Oncology Research (ISSN 2424-7855)
  • Editorial Board Member of ADMET and DMPK (ISSN 1848-7718)
  • Guest Editor — Toxins (Special Issue: Venom and Toxins as Targeted Therapy)
  • Section Editor — Recent Patents on Anti-Cancer Drug Discovery (Special Issue: New Frontiers in Cancer)
Others
Conference Presentations

  • Kwok H. F. (2018) 3rd International Conference on Cancer Research & Targeted Therapy, London, UK. “Anti-TACE antibody drug development for the treatment of cancer”.
  • Li B., Lyu P., Ma R., Mahadevappa R., Xi X. and Kwok H. F. (2017) 6th IAPC Meeting — World Conference on Physico Chemical Methods and World Conference on ADMET and DMPK, Zagreb, Croatia. “Venom-based Peptide Drug Discovery: Enhancing Specificity in Cancer Treatment”. (Invited Keynote Speaker)
  • Yuen S.M., Ye J., Murphy G., Xie R. and Kwok H. F. (2016) 5th IAPC Meeting — Emerging Technologies in Drug Discovery and Development, Zhuhai, China. “Anti-Tumour Effects of a Human & Mouse Cross-Reactive’ Anti-TACE Antibody in a Pancreatic Cancer Model In Vivo”. (Invited Keynote Speaker)
  • Lin Y., Meng C., Lin W., Cheng G. and Kwok H. F. (2016) 3rd Macao Symposium on Biomedical Sciences, Macau SAR. “Regulation of PD-L1 by KRAS and p53”.
  • Li B., Xi X, Chen T., Shaw C. and Kwok H. F. (2015) 18th World Congress of the International Society on Toxinology, Oxford, UK. “High-throughput approach for isolation and identification of novel peptides with anticancer activities from scorpion venoms”.
  • Kwok H. F. (2014) 3rd Antibody & Protein Therapeutics Conference, Boston, USA. “Discovery and Development of Therapeutic TACE (ADAM17) Antibodies”.